PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

News   Apr 16, 2018 | Original story from PhoreMost

 
PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

Dr Chris Torrance, CEO at PhoreMost Ltd

 
 
 

RELATED ARTICLES

Stable Beta-Amyloid Dimers Identified in Alzheimer’s Brains

News

A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.

READ MORE

Protein Target Identified That Could Prevent Strokes

News

Scientists have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.

READ MORE

How Environmental Pollutants and Genetics Work Together in Rheumatoid Arthritis

News

It is well known that individuals with a particular version of human leukocyte antigen have an increased risk for rheumatoid arthritis, but there has been growing interest in the role of environmental pollutants. In a new mouse study, researchers probed the relationship between the two.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE